【Acticor Biotech-Product ACT017】Acticor Biotech Announces the Recruitment of The First Patient in its Phase 2 GARDEN Study in Covid-19_related Ards

Partner News

December 22nd 2020Acticor Biotech released
a piece of news,
which is summarized as follows: 

Approval of phase 2 GARDEN study in France and Brazil

GARDEN will enroll 60 patients hospitalized for COVID19

First Patient included at University Hospital of Strasbourg

Biotech announced the recruitment of the first patient of its phase 2 GARDEN
study to treat COVID-19 _related acute respiratory distress syndrome (ARDS)
with glenzocimab.

phase 2 study, randomized, double blind, multicenter, placebo controlled,
parallel group, exploratory efficacy and safety study of glenzocimab in
sars-cov-2-related acute respiratory distress syndrome. GARDEN will enroll 60
patients in France and in Brazil. The Professor Julien POTTECHER, Strasbourg
University Hospital, is the Principal Investigator of GARDEN in France. The
Professor Victor A. Hamamoto SATO, Hospital Alem?o Oswaldo Cruz in S?o Paulo,
is the Principal Investigator of GARDEN in Brazil.

The first
patient of the GARDEN study has been enrolled in University Hospitals of

The primary
objective of the study is to evaluate the effect of glenzocimab in preventing
clinical progression of disease, when added to standard-of-care in COVID-19
patients presenting with acute respiratory distress syndrome. Glenzocimab might
be an additional treatment option for COVID19 infected patients who present
with ARDS. This treatment might also prevent downstream complications due to
pro-thrombotic conditions.

We are very pleased to have received authorizations
from the health authorities in France and Brazil, respectively ANSM and ANVISA,
to launch our phase 2 GARDEN study in COVID-19_related ARDS with glenzocimab.
The scientific rationale to support the use of glenzocimab in this pathology is
well established and our aim is now to demonstrate clinically its utility. We hope
our product will soon help patients to fight against the disease.” says Dr
Gilles Avenard, CEO and founder of Acticor Biotech.

The original website